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Abstract: Acute kidney injury (AKI) has been increasingly recognized as a risk factor for transition to
chronic kidney disease. Recent evidence suggests that endothelial damage in peritubular capillaries
can accelerate the progression of renal injury. Vasohibin-2 (VASH2) is a novel proangiogenic factor
that promotes tumor angiogenesis. However, the pathophysiological roles of VASH2 in kidney
diseases remain unknown. In the present study, we examined the effects of VASH2 deficiency on the
progression of ischemia–reperfusion (I/R) injury-induced AKI. I/R injury was induced by bilaterally
clamping renal pedicles for 25 min in male wild-type (WT) and Vash2 homozygous knockout mice.
Twenty-four hours later, I/R injury-induced renal dysfunction and tubular damage were more severe in
VASH2-deficient mice than in WT mice, with more prominent neutrophil infiltration and peritubular
capillary loss. After induction of I/R injury, VASH2 expression was markedly increased in injured
renal tubules. These results suggest that VASH2 expression in renal tubular epithelial cells might be
essential for alleviating I/R injury-induced AKI, probably through protecting peritubular capillaries
and preventing inflammatory infiltration.
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1. Introduction
Acute kidney injury (AKI) is an abrupt loss of kidney function, which is characterized by increased
serum creatinine concentration and decreased urine volume within seven days [1]. AKI has traditionally
been recognized as a “transient” disorder; that is, patients with AKI should show complete recovery
of their renal function. However, accumulating evidence suggests that AKI can subsequently result
in the onset of chronic kidney disease (CKD) in some patients [2] and accelerate the progression of
underlying CKD in other patients [3]. Therefore, AKI demonstrates poorer outcomes than previously
reported. Since the pathophysiology of AKI has not yet been fully elucidated, no effective therapeutic
strategies against AKI have been established.
Ischemia–reperfusion (I/R) injury is one of the most common etiology of hospital-acquired AKI.
Although I/R injury is typically accompanied with partial nephrectomy or kidney transplantation,
it has also been recognized to be associated with renal hemodynamic instability, such as sepsis [4].
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Local ischemia results in an imbalance between oxygen supply and demand in the renal tubular
epithelium, and reperfusion induces oxidative stress, leading to apoptosis and necrosis of tubular
epithelial cells. The renal outer medulla and corticomedullary boundary are most susceptible to I/R
injury because of low blood supply relative to high oxygen demand in the area. Recent evidence has
revealed the critical roles of endothelial damage and dysfunction in renal I/R injury [5]. Endothelial
dysfunction not only reduces local blood flow to the tubular epithelium but also enhances infiltration
of inflammatory cells, mainly neutrophils, into the renal interstitium. Previous studies reported that
endothelial nitric oxide synthase (NOS) knockout or NOS inhibitor administration exacerbated the
degree of renal tubular damage caused by renal I/R injury [6,7].
Peritubular capillaries (PTCs) provide oxygen and nutrients to the renal tubules, and ischemic
insult decreases the density of PTC network [8]. The representative proangiogenic factor, vascular
endothelial growth factor (VEGF), is known to be important for maintaining the structure of the
PTC network. It is secreted by glomerular and, to a lesser extent, tubular epithelial cells and acts on
its receptors expressed on glomerular and PTC endothelial cells, respectively [9]. The critical roles
of VEGF in the PTC network have been demonstrated by a recent study, which showed a marked
reduction in the PTC area in renal tubule-specific VEGF knockout mice [10]. Furthermore, previous
studies reported that renal VEGF expression was repressed by I/R injury [11], and administration of
VEGF-121 preserved PTC density in post-I/R kidneys [12], suggesting the potential protective effects of
VEGF on the PTC network in renal I/R injury.
Vasohibin-2 (VASH2) is a novel proangiogenic protein. It was originally identified as a homologue
to vasohibin-1 (VASH1) [13], which is a negative-feedback regulator of angiogenesis. VASH2 expression
is known to be upregulated in cancer cells and promotes cancer angiogenesis as well as growth and
metastasis [14]. Moreover, recent reports demonstrated that VASH2 induced epithelial-to-mesenchymal
transition (EMT) in cancer cells, leading to higher malignancy potential [15]. Although the significance
of VASH2 expression in cancer has become increasingly apparent, the physiological roles of VASH2 in
any organs, including the kidney, remain to be elucidated. Our recent study demonstrated that VASH2
expression in the kidney was increased in diabetic mice [16]. Furthermore, immunohistochemistry for
VASH2 in kidney specimens from patients with CKD revealed increased renal tubular VASH2 staining
compared with control specimens [17]. These findings suggest that VASH2 may be upregulated in the
kidney in response to a variety of insults and involved in renal pathological processes.
In the present study, we examined the pathophysiological significance of VASH2 expression in
I/R-induced AKI using VASH2 knockout mice. Genetic deletion of VASH2 resulted in more severe
renal dysfunction and tubular injury as well as PTC loss and neutrophil infiltration. Furthermore,
renal VASH2 expression in wild-type (WT) mice was upregulated by I/R injury. Our results suggest that
increased renal expression of VASH2 in I/R injury may protect the renal tubular epithelium through
protecting PTCs and preventing inflammatory infiltration.
2. Results
2.1. VASH2 Deficiency Accelerated I/R-Induced Renal Tubular Injury
In accordance with a previous report [16], compared with WT mice, Vash2 homozygous knockout
(Vash2LacZ/LacZ; V2KO) mice did not show any changes in phenotypes, including renal function and
morphology (Figure 1). I/R injury was induced in WT and V2KO mice (WT-I/R and V2KO-I/R,
respectively), and control mice received sham operation (WT-cont and V2KO-cont, respectively).
Although there was no difference in body weight between WT-I/R and V2KO-I/R mice (19.6 ± 1.0 vs.
20.5 ± 2.1 g), the kidney-weight-to-body-weight ratio in V2KO-I/R mice (7.4 ± 0.6 mg/g) tended to be
higher than that in WT-I/R mice (6.8 ± 0.8 mg/g). I/R injury significantly increased blood urea nitrogen
(BUN) and serum creatinine levels in both WT and V2KO mice. However, the increase was more
prominent in V2KO-I/R than WT-I/R mice (Figure 1a,b). I/R-induced renal tubular injury, including
epithelial cell detachment, brush border loss, and intraluminal cast formation was assessed using
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periodic acid-Schiff (PAS)-stained specimens (Figure 1c) and quantified as acute tubular necrosis (ATN)
score. Increased ATN score caused by I/R injury was significantly higher in V2KO-I/R mice than in
WT-I/R mice (Figure 1d). These results suggested that VASH2 deficiency accelerated the renal tubular
damage in I/R-induced AKI.
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Figure 1. Vasohibin-2 (VASH2) deficiency accelerated ischemia–reperfusion (I/R)-induced renal 
dysfunction and renal tubular injury. The increase in serum levels of blood urea nitrogen (BUN) (a) 
and creatinine (b) induced by I/R injury was higher in V2KO mice than WT mice; (c) light microscopy 
images of the renal corticomedullary areas (periodic acid-Schiff (PAS) staining, original
magnification, ×200). (d) Acute tubular necrosis (ATN) score was calculated based on the percentage 
of damaged tubules. n = 6 for each group. * p < 0.01 vs. WT-cont, # p < 0.05 vs. WT-I/R. Each column 
shows the mean ± standard deviation (SD). 
2.2. VASH2 Deficiency Promoted I/R-Induced Oxidative Stress Accumulation and Apoptosis 
Consistent with renal tubular injury, oxidative stress markers were accumulated in the kidney
after I/R injury. Immunohistochemistry revealed the accumulation of the representative lipid 
peroxide, malondialdehyde (MDA), in injured renal tubules (Figure 2a), and immunoblotting 
showed increased renal levels of another oxidative stress marker, 4-hydroxy-nonenal (4-HNE), in I/R
injury (Figure 2b). The accumulation of MDA and 4-HNE was more prominent in V2KO-I/R mice 
than in WT-I/R mice (Figure 2a,b). Apoptotic cells in the kidney were evaluated by terminal uridine 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. A significantly 
larger number of apoptotic cells were detected in V2KO-I/R mice than in WT-I/R mice (Figure 2c,d).
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Figure 1. asohibin-2 ( S 2) deficiency accelerated ische ia–reperfusion (I/ )-induced renal
dysfunction and renal tubular injury. The increase in serum levels of blood urea nitrogen (BUN) (a) and
creatinine (b) induced by I/R injury was higher in V2KO mice than WT ice; (c) li t icr sc y
i s of the renal corticomedullary areas (periodic acid-Schiff (PA ) staining, original magnification,
×200). (d) Acute tubular necrosis (ATN) sc re was calculated based on the percentage of damaged
tubules. n = 6 for ach group. * p < 0.01 vs. WT-cont, # p < 0.05 vs. WT-I/R. Each column shows the
mean ± stand rd deviation (SD).
2.2. VASH2 Deficiency Promoted I/R-Induced Oxidative Stress Accumulation and Apoptosis
Consistent with renal tubular injury, oxidative stress markers were accumulated in the kidney
after I/R injury. Immunohistochemistry revealed the accumulation of the representative lipid peroxide,
malondialdehyde (MDA), in injured renal tubules (Figure 2a), and immunoblotting showed increased
renal levels of another oxidative stress marker, 4-hydroxy-nonenal (4-HNE), in I/R injury (Figure 2b).
The accumulation of MDA and 4-HNE was more prominent in V2KO-I/R mice than in WT-I/R mice
(Figure 2a,b). Apoptotic cells in the kidney were evaluated by terminal uridine deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) staining. A significantly larger number of
apoptotic cells were detected in V2KO-I/R mice than in WT-I/R mice (Figure 2c,d).
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Figure 2. VASH2 deficiency promoted oxidative stress marker accumulation and apoptosis in I/R-
induced acute kidney injury (AKI). (a) Immunohistochemical images of malondialdehyde (MDA) 
accumulation in the kidney (original magnification, ×200). (b) Immunoblots for 4-hydroxy-nonenal
(4-HNE) and β-actin. Each lane was loaded with 40 µg of protein. MM, molecular weight. (c) 
Representative images for terminal uridine deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling (TUNEL) staining in the kidney. The apoptotic nuclei were stained blue. (d) A larger number 
of TUNEL-positive nuclei were found in V2KO-I/R mice than in WT-I/R mice. n = 6 for each group. * 
p < 0.01 vs. WT-cont, # p < 0.05 vs. WT-I/R. Each column shows the mean ± SD. 
2.3. VASH2 Deficiency Enhanced Neutrophil Infiltration in I/R-Induced Renal Tubular Injury 
Neutrophil infiltration is known to be an important contributor to the development of I/R-
induced renal tubular injury. The number of Ly-6B.2-positive neutrophils in the kidney was 
examined. Neutrophil infiltration was significantly increased by I/R injury in WT mice, whereas the 
increase in infiltration was more prominent in V2KO-I/R mice than in WT-I/R mice (Figure 3a,b). The
expression of two major neutrophil chemoattractants, CXCL2 and CXCL5, was increased by I/R 
injury, and the increase in expression of these chemokines was higher in V2KO-I/R mice than in WT-
I/R mice (Figure 3c, d). Immunohistochemistry revealed increased CXCL2 expression in injured renal 
tubular epithelium (Figure 3e) with the number of CXCL2-positive tubules being significantly higher 
in V2KO-I/R mice than WT-I/R mice (Figure 3f). 
Figure 2. VASH2 deficiency promoted oxidative stress marker accumulation and apoptosis in
I/R-induced acute kidney injury (AKI). (a) Immunohistochemical images of malondialdehyde (MDA)
accumulation in the kidney (original magnification, ×200). (b) Immunoblots for 4-hydroxy-nonenal
(4-HNE) and β-actin. Each lane was loaded with 40 µg of protein. M, molecular weight.
(c) Representative images for terminal uridine deoxynucleotidyl transferase- ediated dUTP nick-end
labeling (TUNEL) staining in the kidney. The apoptotic nuclei were stained blue. (d) A larger nu ber
of TUNEL-positive nuclei were found in 2 -I/ ice than in T-I/ ice. n 6 for each group.
* p 0.01 vs. T-cont, p < 0.05 vs. WT-I/R. Each column shows the mean ± SD.
2.3. VASH2 Deficiency Enhanced Neutrophil Infiltration in I/R-Induced Renal Tubular Injury
Neutrophil infiltration is known to be an important contributor to the development of I/R-induced
renal tubular injury. The number of Ly-6B.2-positive neutrophils in the kidney was examined.
Neutrophil infiltration was significantly increased by I/R injury in WT mice, whereas the increase in
infiltration was more prominent in V2KO-I/R mice than in WT-I/R mice (Figure 3a,b). The expression of
two major neutrophil chemoattractants, CXCL2 and CXCL5, was increased by I/R injury, and the increase
in expression of these chemokines was higher in V2KO-I/R mice than in WT-I/R mice (Figure 3c,d).
Immunohistochemistry revealed increased CXCL2 expression in injured renal tubular epithelium
(Figure 3e) with the number of CXCL2-positive tubules being significantly higher in V2KO-I/R mice
than WT-I/R mice (Figure 3f).
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Figure 3. VASH2 deficiency accelerated neutrophil infiltration in I/R-induced kidney injury. (a) 
Immunohistochemical images of Ly-6B.2, a marker for neutrophils, in the kidney (original 
magnification, ×200). (b) The number of Ly-6B.2-positive cells was higher in V2KO-I/R mice than WT-
I/R mice; (c) Cxcl2 and (d) Cxcl5 mRNA expression in the kidney. Data were normalized with the 
expression of 18S rRNA. (e) Immunohistochemical images of CXCL2 (original magnification, ×200). 
CXCL2-positive tubules are indicated by arrows. (f) The number of CXCL2-positive tubules was 
higher in V2KO-I/R mice than WT-I/R mice. n = 6 for each group. * p < 0.01 vs. WT-cont, # p < 0.05 vs. 
WT-I/R. Each column shows the mean ± SD. 
2.4. VASH2 Deficiency Accelerated PTC Loss in I/R-Induced Kidney Injury 
PTCs are essential for normal tubular function as they deliver oxygen and nutrients to tubular
epithelial cells. I/R-injury-induced PCT loss has been shown in previous studies [18]. In the present 
study, the number of CD34-positive PTCs was significantly decreased by I/R injury in WT mice. Such 
PTC loss was more prominent in V2KO mice than WT mice (Figure 4a,b). Renal VEGF-A expression 
was also significantly decreased by I/R injury. However, there were no differences in VEGF-A mRNA
levels between WT-I/R and V2KO-I/R mice (Figure 4c). I/R-injury-induced PTC damage is known to 
Figure 3. VASH2 deficiency accelerated neutrophil infiltration in I/R-induced kidney injury.
(a) Immunohistochemical images of Ly-6B.2, a marker for neutrophils, in the kidney (original
magnification, ×200). (b) The number of Ly-6B.2-positive cells was higher in V2KO-I/R mice than
WT-I/R mice; (c) Cxcl2 and (d) Cxcl5 mRNA expression in the kidney. Data were normalized with the
expression of 18S rRNA. (e) Immunohistochemical images of CXCL2 (original magnification, ×200).
CXCL2-positive tubules are indicated by arrows. (f) The number of CXCL2-positive tubules was higher
in V2KO-I/R mice than WT-I/R mice. n = 6 for each group. * p < 0.01 vs. WT-cont, # p < 0.05 vs. WT-I/R.
Each column shows the mean ± SD.
2.4. VASH2 Deficiency Accelerated PTC Loss in I/R-Induced Kidney Injury
PTCs are essential fo normal tubular function a they deliver xygen and nutrients to tubular
epithelial cells. I/R-injury-induced PCT loss ha been shown in previous studies [18]. In the present
study, the number f CD34-positive PTCs was significantly decreased by I/R injury in WT mice.
Such PTC loss was more prominent in V2KO mice than WT mice (Figure 4a,b). Renal VEGF-A
expression was also significantly decreased by I/R injury. However, there were no differences in
VEGF-A mRNA levels between WT-I/R and V2KO-I/R mice (Figure 4c). I/R-injury-induced PTC
damage is known to be associated with increased expression of intercellular adhesion molecule-1
(ICAM-1). Here, renal ICAM-1 expression was upregulated by I/R injury. Although the increase
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in ICAM-1 expression tended to greater in V2KO-I/R mice than that in WT-I/R mice, the difference
was not statistically significant (Figure 4d). The protein levels of VEGF-A (Figure 4e,g) and ICAM-1
(Figure 4f,h) followed the same tendency as their respective mRNA levels, and there were no significant
differences in protein levels of either VEGF-A or ICAM-1 between V2KO-IR and WT-I/R mice.
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Figure 4. VASH2 deficiency accelerated I/R-induced peritubular capillary (PTC) loss in the 
kidney. (a) Immunohistochemical images of the endothelial marker CD34 in the kidney (original 
magnification, ×200). (b) The decrease in the number of CD34-positive PTCs was greater in V2KO-
I/R mice than WT-I/R mice; (c) Vegfa and (d) Icam1 mRNA expression in the kidney. Data were 
normalized with expression of 18S rRNA. (e,f) Immunoblots to quantify protein levels of VEGF-A 
Figure 4. VASH2 deficiency accelerated I/R-induced peritubular capillary (PTC) loss in the kidney.
(a) Immunohistochemical images of the endothelial marker CD34 in the kidney (original magnification,
×200). (b) The decrease in the number of CD34-positive PTCs was greater in V2KO-I/R mice than WT-I/R
mice; (c) Vegfa and (d) Icam1 mRNA expression in the kidney. Data were normalized with expression of
18S rRNA. (e,f) Immunoblots to quantify protein levels of VEGF-A and ICAM-1, respectively. VEGF-A
bands were observed at 24 kDa. Each lane was loaded with 40 µg of protein. (g,h) Densitometric
analysis of the immunoblots. Data were normalized to β-actin. n = 6 for each group. * p < 0.01 vs.
WT-cont, # p < 0.05 vs. WT-I/R. Each column shows the mean ± SD.
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2.5. Endogenous VASH2 Expression in I/R-Induced Kidney Injury
Renal Vash2 mRNA expression in WT-cont and WT-I/R mice was examined by real-time PCR. I/R
injury remarkably increased Vash2 expression in the kidney (Figure 5a). As β-galactosidase (β-gal) gene
was inserted into the allele of Vash2 gene in V2KO (Vash2LacZ/LacZ) mice [19], the localization of β-gal
under the control of Vash2 promoter was identified by immunostaining of β-gal in the kidney from
V2KO mice. β-gal-positive renal tubular epithelial cells were not detected in the kidney without I/R
injury, whereas a large number of β-gal-positive renal tubules was observed after I/R injury (Figure 5b).
These results suggested that VASH2 expression was markedly upregulated in renal tubular epithelial
cells in response to I/R-induced renal injury.
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Figure 5. Endogenous VASH2 expression in the kidney in response to I/R injury. (a) Vash2 mRNA 
levels determined by real-time PCR in the kidneys from WT-cont and WT-I/R mice. n = 6 for each 
group. Data were normalized with the expression of 18S rRNA. (b) Immunofluorescence staining for 
β-galactosidase (β-gal) to detect β-gal expression in the kidneys from V2KO-cont (left) and V2KO-
I/R (right) mice. For nuclear staining, 4′,6-diamidino-2- phenylindole (DAPI) was used (original 
magnification, × 200). * p < 0.01 vs. WT-cont. The column shows the mean ± SD. 
3. Discussion
In the present study, genetic deletion of a novel proangiogenic factor VASH2 resulted in 
exacerbation of renal I/R-induced kidney injury, with enhanced neutrophil infiltration and PTC loss. 
VASH2 expression was markedly upregulated by I/R injury-induced renal tubular damage,
suggesting that increased expression of VASH2 was essential for alleviating acute tubular damage in 
renal I/R injury. 
Renal I/R injury is a common etiology in human AKI, such as in kidney transplantation. Its 
pathogenesis has long been investigated in experimental and clinical studies. Ischemia reduces blood
flow to renal tubular epithelial cells, especially in the outer medulla, and reperfusion can increase 
oxidative stress, leading to renal tubular cell apoptosis, as shown in Figures 1 and 2. In such processes, 
mitochondrial dysfunction might contribute to generate high levels of reactive oxygen species (ROS), 
which are necessary to initiate and maintaining renal tubular injury. Since excessive mitochondrial 
ROS production induces peroxidation of unsaturated fatty acids, increased accumulation of lipid 
peroxidation products, including 4-HNE and MDA, in the kidney might reflect the onset of both 
oxidative stress and mitochondrial dysfunction in AKI. Therefore, the detection of higher levels of
these lipid peroxidation products in the kidney of V2KO-I/R mice suggests that VASH2 protects 
mitochondria from I/R injury. However, recent evidence has revealed the importance of 
inflammation and microvascular damage in the progression of renal I/R injury. The earliest
population of the inflammatory cells that infiltrate into the renal interstitium is neutrophils [20]. 
Figure 5. Endogenous VASH2 expression in the kidney in response to I/R injury. (a) Vash2 mRNA
levels determined by real-time PCR in the kidneys from T-cont and T-I/R ice. n = 6 for each
group. Data were normalized wit the expressi n of 18S rRNA. (b) Immun fluorescence staining
for β-galactosidase (β-gal) to detect β-gal expression in the kidneys from V2KO-cont (left) and
V2KO-I/R (right) mice. For nuclear staining, 4′,6-diamidino-2- phe ylindole (DAPI) was used (original
agnification, × 2 0). * p < .01 vs. WT-cont. The column shows the mean ± SD.
3. Discussion
In the present study, genetic deletion of a novel proangiogenic factor VASH2 resulted in
exacerbation of renal I/R-induced kidney injury, with enhanced neutrophil infiltration and PTC
loss. VASH2 expression was markedly upregulated by I/R injury-induced renal tubular damage,
suggesting that increased expression of VASH2 was essential for alleviating acute tubular damage in
renal I/R injury.
Renal I/R injury is a common etiology in human AKI, such as in kidney transplantation.
Its pathogenesis has long been investigated in experimental and clinical studies. Ischemia reduces
blood flow to renal tubular epithelial cells, especially in the outer medulla, and reperfusion can increase
oxidative stress, leading to renal tubular cell apoptosis, as shown in Figures 1 and 2. In such processes,
mitochondrial dysfunction might contribute to generate high levels of reactive oxygen species (ROS),
which are necessary to initiate and maintaining renal tubular injury. Since excessive mitochondrial
ROS production induces peroxidation of unsaturated fatty acids, increased accumulation of lipid
peroxidation products, including 4-HNE and MDA, in the kidney might reflect the onset of both
oxidative stress and mitochondrial dysfunction in AKI. Therefore, the detection of higher levels of
these lipid peroxidation products in the kidney of V2KO-I/R mice suggests that VASH2 protects
mitochondria from I/R injury. However, recent evidence has revealed the importance of inflammation
and microvascular damage in the progression of renal I/R injury. The earliest population of the
inflammatory cells that infiltrate into the renal interstitium is neutrophils [20]. Neutrophil infiltration
can be induced by increased expression of neutrophil chemoattractants, such as CXCL1, CXCL2, and
CXCL5. These chemokines have been demonstrated to be upregulated in renal tubular cells in response
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to I/R injury [21]. However, microvascular damage also contributes to the inflammatory cell infiltration.
Renal I/R-injury-induced endothelial damage results in PTC rarefaction and accelerates reduced blood
flow to renal tubular cells. Concurrently, I/R injury is known to upregulate ICAM-1 expression in the
PTC endothelial cells, leading to the promotion of neutrophil adhesion and migration into the renal
interstitium [22]. Thus, inflammation and endothelial damage are closely related, and both contribute
to the progression of renal I/R injury.
VASH2 is a novel proangiogenic factor. It was demonstrated that exogenous VASH2 persistently
increased vascularity, whereas VASH2 deficiency resulted in a lower vascular density in a murine
subcutaneous angiogenesis model [19]. In addition, VASH2 expression was associated with accelerated
angiogenesis in human ovarian cancer [14], and downregulation of VASH2 in endometrial cancer
cells inhibited tumor angiogenesis [23]. VASH2 was originally identified as a homolog of VASH1 [13],
an endothelium-derived antiangiogenic factor. However, contrary to VASH1, the main source of VASH2
does not seem to be endothelial cells. Notably, VASH2 has been reported to be highly expressed in
embryonic stem cells and induced pluripotent stem cells [24], whereas it is scarcely expressed in various
types of differentiated cells, including epithelial and endothelial cells. Therefore, the physiological
roles of VASH2 remain to be elucidated. Although VASH1 and VASH2 have opposite effects on
tumor angiogenesis, they may not always exert opposite functions in various pathological processes.
VASH1 is constitutively expressed in endothelial cells, and it has been shown that VASH1 expression is
important to enhance cellular stress tolerance [25]. We recently reported that heterozygous deficiency
of VASH1 exacerbated cisplatin-induced AKI through PTC damage and inflammatory infiltration [26].
This report, along with the present study, suggests that both VASH1 and VASH2 are required to prevent
the progression of AKI.
As mentioned above, VASH2 is barely expressed in differentiated cells. Therefore, almost all tissues
and organs, including the kidney, display extremely low VASH2 expression. However, once normal
differentiated cells are transformed into cancer cells, such cell populations acquire the ability to highly
express VASH2 [14,27]. In addition, VASH2 expression has been associated with cancer progression and
poor prognosis in various malignancies, such as pancreatic and esophageal cancers [28,29]. Therefore,
most cells may have the potential to upregulate VASH2 expression during cellular transformation.
In our recent report, we showed that renal VASH2 expression was significantly increased in a diabetic
nephropathy mouse model [16]. Furthermore, in the kidney specimens from patients with CKD,
immunohistochemical analysis demonstrated that renal tubular staining for VASH2 was detected in
the patients but not in the control subjects [17]. Consistent with these findings, our current findings
also revealed that I/R injury markedly induced VASH2 expression in the renal tubules, suggesting that
the injured tubular cells might be transformed to upregulate VASH2. Unfortunately, the regulatory
mechanisms of VASH2 expression are yet to be elucidated. Although VASH1 was shown to inhibit
endothelial proliferation partially through the degradation of the hypoxia-inducible factor (HIF)-1α
in vitro [30], an association between VASH2 and HIF-1α has not been clearly demonstrated. However,
considering that hypoxia can promote cancer angiogenesis and EMT [31], enhanced VASH2 expression
in cancer cells may occur in response to hypoxia. Similarly, ischemic insult in the kidney may also
induce VASH2 expression in tubular cells, and renal I/R injury may specifically upregulate VASH2
compared with other etiologies of AKI. Such hypotheses should be explored in future research.
Recently, a study demonstrated that renal tubules-specific deletion of VEGF-A led to a markedly
reduced PTC area, suggesting that VEGF-A expressed in renal tubular cells is important for maintaining
normal PTC structure and function [10,32]. Since VASH2 is also a proangiogenic factor, renal
tubule-derived VASH2 may protect PTCs from various insults, similar to VEGF-A. Here, VASH2
deficiency resulted in prominent I/R-injury-induced PTC loss, although there were no differences in renal
VEGF-A levels between WT-I/R and VASH2-I/R mice. In various gastric cancer cell lines, the mRNA
expressions of VASH2 has been reported to be inconsistent with that of VEGF [33]. Thus, VASH2 may
promote angiogenesis independently of VEGF. As mentioned above, renal ischemic insults upregulate
ICAM-1 expression in PTC endothelial cells, leading to increased neutrophil infiltration into the
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renal interstitium. In this study, VASH2 deficiency mice displayed a higher number of infiltrated
neutrophils in the kidney than in WT mice, and although renal ICAM-1 expression tended to be higher
in V2KO-I/R mice than WT-I/R mice, the difference was not statistically significant. These results
suggested that the increased expression of chemoattractants in the renal tubular cells, rather than
higher ICAM-1 expression triggered by endothelial damage, was responsible for a more prominent
neutrophil infiltration in V2KO-I/R mice.
Taken together, renal VASH2 expression has some protective effects in I/R injury-related AKI.
However, VASH2 is not always good for the kidney. In a diabetic nephropathy mouse model, VASH2
deficiency ameliorated albuminuria and glomerular injury [16]. In addition, recent evidence suggested
that VASH2 not only promotes tumor angiogenesis but also induces EMT in cancer cells, thus enhancing
the malignant behavior. EMT is a process that is involved in the dedifferentiation of mature epithelial
cells. Overexpression of VASH2 in human hepatocellular carcinoma cells induced the expression of
the EMT-related nuclear factor, zinc finger E-box-binding homeobox 2 (ZEB2), and the mesenchymal
marker vimentin [15], whereas knockdown of VASH2 in ovarian cancer cells inhibited the expression
of ZEB2 and mesenchymal markers [34]. Considering the pathological roles of EMT in renal fibrosis,
sustained expression of VASH2 in renal tubular epithelial cells after I/R injury may accelerate post-AKI
interstitial fibrosis. Although VASH2 exerts protective effects on I/R injury in the acute phase, it may
paradoxically exert adverse effects during the recovery phase. Thus, based on the results of this study,
whether a therapeutic strategy that enhances VASH2 expression in tubular epithelial cells might be
effective for I/R injury-induced AKI remains undetermined.
This study has a limitation that whole body, but not conditional, V2KO mice were used in
the animal experiments. Since increased VASH2 expression was observed in renal tubular cells
in WT-I/R mice (Figure 5), we believed that VASH2 deficiency in renal tubular epithelial cells was
closely associated with the exacerbation of renal I/R injury. However, other minor source-derived
VASH2 might affect the results in this study. Considering that VASH2 was found be localized in
bone-marrow-derived mononuclear cells in a skin-flap angiogenesis model [19,35], inflammatory cells
may be a minor source of VASH2 in an I/R model, although mononuclear cells are hardly detected in
the acute phase of renal I/R injury. Since it is currently impossible for us to use conditional V2KO mice,
whether such minor-source-derived VASH2 affected the results could not be determined in this study.
Another potential limitation of this study is the small number of mice used for each group. Although
WT-I/R and V2KO-I/R mice displayed significant differences in renal injury, more replicates might
be needed to clarify the underlying mechanisms by which VASH2 exerted protective effects in AKI,
including ICAM-1 expression.
In conclusion, increased expression of proangiogenic factor VASH2 may be essential to prevent
the progression of renal tubular injury in I/R-induced AKI, possibly through protecting PTCs and
preventing inflammatory infiltration. Although further studies are needed to clarify the physiological
and pathological roles of VASH2 in the kidney, VASH2 expression may be a novel target for the acute
phase of AKI.
4. Materials and Methods
4.1. Animals and Experimental Protocols
C57BL/6J Vash2 homozygous knockout (Vash2LacZ/LacZ; V2KO) mice were obtained from the
Institute of Development, Aging, and Cancer, Tohoku University (Sendai, Japan). The experimental
protocol was approved by the Animal Care and Use Committee in Okayama University (Okayama,
Japan; approval number OKU-2014509 [17/10/2014] and OKU-2017345 [24/08/2017]). Eight-week-old
male C57BL/6J WT and V2KO mice were fed a standard pellet laboratory chow and provided with water
ad libitum. Renal I/R injury in WT and V2KO mice was induced by clipping bilateral renal pedicles
with plastic clips for 25 min. Control WT and V2KO mice received sham operation. Twenty-four hours
later, blood samples were collected from the inferior vena cava of mice under anesthesia, and then the
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kidneys were harvested. The experimental subgroups included (1) control WT (WT-cont), (2) control
V2KO (V2KO-cont), (3) WT with I/R injury (WT-I/R), and (4) V2KO with I/R injury (V2KO I/R) mice
(n = 6 in each group). Serum creatinine and BUN concentrations were measured by FUJIFILM Monolith
Co., Ltd. (Tokyo, Japan).
4.2. Histological Analysis
For histological analysis, 10% buffered formalin-fixed and paraffin-embedded 4 µm sections were
stained with PAS for observation by light microscopy. Renal tubular injury was quantified as ATN
score, defined as the percentage of renal tubules with detachment of epithelium, loss of brush border,
or cast formation at 200× magnification, as follows: 0 = none, 1 = <10%, 2 = 10–25%, 3 = 26–50%,
4 = 51–75%, and 5 = >75% [36]. The kidney sections were evaluated by two investigators (H.M. and
K.T.) in a blinded manner.
4.3. Immunohistochemistry
Kidney sections (4 µm) fixed with 10% buffered formalin and embedded in paraffin were
used for MDA, CXCL2, and CD34 immunohistochemistry, as previously described [37,38].
After deparaffinization with xylene and rehydration with ethanol, the sections were treated with
3% H2O2 for 10 min to inactivate endogenous peroxidase activity. For CD34 staining, the sections
were then treated with 10 mM citrate buffer (pH 6.0) for 10 min in a microwave for antigen retrieval.
After incubation with serum-free Protein Block (Dako, Glostrup, Denmark) for 30 min, the sections were
incubated with mouse monoclonal anti-MDA (JaICA, Fukuroi, Shizuoka, Japan), rabbit anti-CXCL2
(Abcam, Cambridge, UK), and rat anti-CD34 (Abcam, Cambridge, UK) antibodies overnight at 4 ◦C.
Sections were then incubated with MACH2 Mouse or Rabbit HRP-Polymer (Biocare Medical, Pacheco,
CA, USA) for MDA and CXCL2, respectively, and biotinylated anti-rat IgG (Vector Laboratories,
Burlingame, CA, USA) followed by VECTASTAIN Elite ABC Kit (Vector laboratories, Burlingame,
CA, USA) for CD34. ImmPACT DAB (Vector Laboratories, Burlingame, CA, USA) was used as a
chromogen. The nuclei were counterstained with hematoxylin. The number of CXCL2-positive tubules
was counted at 200 ×magnification in ten fields of view per section. The number of CD34-positive
PTCs was counted at 200 ×magnification in ten fields of view per section.
For immunohistochemical detection of neutrophils, 4 µm frozen kidney sections fixed with
methanol were used. After endogenous peroxidase inactivation, the sections were incubated with
anti-Ly-6B antibody (Bio-Rad, Hercules, CA, USA) overnight at 4 ◦C, followed by incubation with
HRP-conjugated anti-rat IgG (Vector laboratories, Burlingame, CA, USA) for 60 min at room temperature.
ImmPACT DAB was then applied, followed by counterstaining with hematoxylin. The number of
Ly-6B-positive neutrophils was counted at 200 ×magnification in ten fields of view per section.
4.4. Apoptosis Detection
TACS 2 TdT-Blue Label In Situ Apoptosis Detection Kit (Trevigen, Gaithersburg, MD, USA) was
used to detect TUNEL-positive apoptotic cells in 8 µm frozen sections of the kidneys, according to the
manufacturer’s protocol [39]. The nuclei were counterstained with Nuclear Fast Red. Ten fields of view
per section at 200 ×magnification were evaluated to determine the average number of apoptotic cells.
4.5. Immunofluorescence
Immunofluorescence was performed on 4 µm frozen kidney sections fixed with methanol,
as previously described [16,40]. After treatment with phosphate-buffered saline containing 0.1% Tween
20 for penetration, the sections were incubated with anti-β-gal antibody (Promega, Madison, WI, USA)
overnight at 4 ◦C, followed by incubation with Alexa Fluor 488-labeled secondary antibody (Thermo
Fischer Scientific, Waltham, MA, USA). DAPI (Millipore, Burlington, MA, USA) was used for nuclear
staining. The images were obtained by fluorescence microscopy (BZ-8000; Keyence, Osaka, Japan).
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4.6. Immunoblotting
Kidney tissues containing cortex and medulla were homogenized in RIPA lysis buffer (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at 4 ◦C. Cultured cell lysates were prepared as described
below. Extracted protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred onto nitrocellulose membranes [16]. The membranes were incubated
overnight at 4 ◦C with the following primary antibodies: (1) anti-4-HNE antibody (JaICA, Fukuroi,
Shizuoka, Japan), (2) rabbit anti-VEGF-A antibody (Proteintech, Rosemont, IL, USA), (3) rabbit
anti-ICAM-1 antibody (Proteintech, Rosemont, IL, USA), and (4) anti-β-actin antibody (Sigma-Aldrich,
St Louis, MO, USA). Then, they were incubated with HRP-labeled anti-mouse or anti-rabbit IgG
antibody (Cell Signaling Technology, Danvers, MA, USA) for 60 min, and signals were detected
using ECL Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK). Images were
obtained with ImageQuant LAS 4000 (GE Healthcare, Buckinghamshire, UK). Band density was
determined by densitometry using the ImageJ software (version 1.51) and expressed relative to the
density of β-actin.
4.7. Real-Time PCR
RNA was extracted from the homogenized kidney tissues using RNeasy Mini Kit (Qiagen,
Chatsworth, CA, USA) according to the manufacturer’s protocol and reverse transcribed into cDNA
with random primers and SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
cDNA was added to Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) with
specific oligonucleotide primers for the detection of mRNA levels, as previously described [26,39].
Quantitative real-time PCR was performed on the StepOnePlus Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). The amount of PCR products was normalized with 18S rRNA.
The following oligonucleotide primers were used: mouse Cxcl2, 5′-GCC AAG GGT TGA CTT CAA
GAA CA-3′ (forward) and 5′-AGG CTC CTC CTT TCC AGG TCA-3′ (reverse); mouse Cxcl5, 5′-TGA
TCC CTG CAG GTC CAC A-3′ (forward) and 5′-CTG CGA GTG CAT TCC GCT TA-3′ (reverse); mouse
Vegfa, 5′-ACA TTG GCT CAC TTC CAG AAA CAC-3′ (forward) and 5′-TGG TTG GAA CCG GCA
TCT TTA-3′ (reverse); mouse Icam1, 5′-AAC TGT GGC ACC GTG CAG TC-3′ (forward) and 5′-AGG
GTG AGG TCC TTG CCT ACT TG-3′ (reverse); mouse Vash2, 5′-GGC TAA GCC TTC AAT TCC CC-3′
(forward) and 5′-CCC ATT GGT GAG ATA GAT GCC-3′ (reverse); mouse 18S rRNA, 5′-ACT CAA
CAC GGG AAA CCT CA-3′ (forward) and 5′-AAC CAG ACA AAT CGC TCC AC-3′ (reverse).
4.8. Statistical Analysis
All values were expressed as means ± SD. Kruskal–Wallis test followed by post-hoc Dunn’s
multiple comparison test was used for inter-group comparisons of multiple variables. The JMP 10
software (SAS Institute Inc, Cary, NC, USA) was used for statistical analyses. p < 0.05 was regarded as
statistically significant.
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Abbreviations
AKI Acute kidney injury
VASH2 Vasohibin-2
CKD Chronic kidney disease
I/R Ischemic reperfusion
NOS Nitric oxide synthase
PTC Peritubular capillary
VEGF Vascular endothelial growth factor
WT Wild-type
V2KO VASH2 knockout
ATN Acute tubular necrosis
MDA Malondialdehyde
4-HNE 4-hydroxy-nonenal
TUNEL Terminal uridine deoxynucleotidyl transferase-mediated dUTP nick-end labeling
CXCL CXC chemokine ligand
ICAM-1 Intercellular adhesion molecule-1
β-gal β-galactosidase
ROS Reactive oxygen species
EMT Epithelial-to-mesenchymal transition
ZEB2 zinc finger E-box-binding homeobox 2
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